The Anticancer Drug Cytarabine Does not Interact with the Human Erythrocyte Membrane

Zeitschrift fur Naturforschung - Section C Journal of Biosciences

Volumn 58, Issue 11-12, 2003, Pages 885-890

  Suwalsky, Mario ^a   Hernández, Pedro L ^a   Villena, Fernando ^a   Sotomayor, Carlos P ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE VALPARAÍSO   (Chile)

Author keywords

Cytarabine; Erythrocyte Membrane; Phospholipid Bilayer

Indexed keywords

EID: 0346966845     PISSN: 09395075     EISSN: None     Source Type: Journal    
DOI: 10.1515/znc-2003-11-1225     Document Type: Article

References (27)

1. Belt J. A., Marina N. M., Phelps D. A., and Crawford C. R. (1993), Nucleoside transport in normal and neoplastic cells. Adv. Ezyme Regul. 33, 235-252.
2. Bishop J. F., Matthews J. P., Young G. A., Bradstock K., and Lowenthal R. M. (1998), Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group. Leuk. Lymphoma 28, 315-327.
3. Boon J. M. and Smith B. D. (2002), Chemical control of phospholipid distribution across bilayer membranes. Med. Res. Rev. 22, 251-281.
4. Devaux P. F. and Zachowsky A. (1994), Maintenance and consequences of membrane phospholipid asymmetry. Chem. Phys. Lipids 73, 107-120.
5. Dodge J. T., Mitchell C., and Hanahan D. J. (1963), The preparation and chemical characterization of hemoglobin-free ghosts of human erythrocytes. Arch. Biochem. Biophys. 100, 119-130.
6. Donehower R. C., Karp J. E., and Burke P. J. (1986), Pharmacology and toxicity of high dose cytarabine by 72-hour continuous infusion. Cancer Treat. Rep. 70, 1059-1065.
7. Feldman E. J. (2000), High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia. Leuk. Res. 24, 189-191.
8. Gati W. P., Paterson A. R., Larratt L. M., Turner A. R., and Belch A. R. (1997), Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. Blood 90, 346-353.
9. Gati W. P., Paterson A. R., Belch A. R., Chlumecky V., Larratt L. M., Mant M. J., and Turner A. R. (1998), Es nucleoside transporter content of acute leukemia cells: role in cell sensitivity to cytarabine (araC). Leuk. Lymphoma 32, 45-54.
10. Gmeiner W. H., Skradis A., Pon R. T., and Liu J. (1998), Cytarabine-induced destabilization of a model Okazaki fragment. Nucleic Acids Res. 26, 2359-2365.
11. Grunicke H. and Hoffmann J. (1992), Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol. Ther. 55, 1-30.
12. Higashigawa M., Ido M., Kuwabara H., Hori H., Ohkubo T., Kawasaki H., Sakurai M., Taniguchi K., and Hamazaki M. (1991), Membrane transport of 1-beta-D-arabinofuranosylcytosine and accumulation of 1-beta-D- arabinofuranosylcytosine 5′-triphosphate in P388 murine leukemic cells resistant to vincristine. Leuk. Res. 15, 255-262.
13. Jamieson G. P., Snook M. B., Bradley T. R., Bertoncello I., and Wiley J. S. (1989), Transport and metabolism of 1-β-D-arabinofuranosylcytosine in human ovarian adenocarcinoma cells. Cancer Res. 49, 309-313.
14. Kantar M., Cetingul N., and Kavakli K. (1999), Brief Report: Skin toxicity after administration of low-dose cytarabine. Med. Ped. Oncol. 33, 420-421.
15. Luxo C., Jurado A. S., Custodio J. B. A., and Madeira V. M. (1996), Use of Bacillus stearothermophilus as a model to study tamoxifen-membrane interactions. Toxicol. In vitro 10, 463-471.
16. Marutaka M., Iwagachi H., Suguri T., Tanaka N., and Orita K. (1994), Alterations of membrane fluidity in K562 cells exposed to the anticancer drug adriamycin. Res. Commun. Mol. Pathol. Pharmacol. 85, 163-170.
17. Parasassi T. and Gratton E. (1995), Membrane lipid domains and dynamics as detected by Laurdan fluorescence. J. Fluorescence 5, 59-69.
18. Roelofsen R. (1991), Molecular architecture and dynamics of the plasma membrane lipid bilayer: the red blood cell as a model. Infection (Suppl. 4) 19, S206-S209.
19. Sheetz M. P. and Singer S. J. (1974), Biological membranes as bilayer couples. A molecular mechanism of drug induced interactions. Proc. Natl. Acad. Sci. USA 71, 4457-4461.
20. Speelmans G., Staffhorst R. W. H. M., Versluis K., Reedijk J., and de Kruijff B. (1997), Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 36, 10545-10550.
21. Suwalsky M., Hernández P., Villena F., Aguilar F., and Sotomayor C. P. (1998), Interaction of the anticancer drug tamoxifen with the human erythrocyte membrane and molecular models. Z. Naturforsch. 53c, 182-190.
22. Suwalsky M., Hernández P., Villena F., Aguilar F., and Sotomayor C. P. (1999a), The anticancer drug adriamycin interacts with the human erythrocyte membrane. Z. Naturforsch. 54c, 271-277.
23. Suwalsky M., Hernández P., Villena F., and Sotomayor C. P. (1999b), The anticancer drug chlorambucil interacts with the human erythrocyte membrane and model phospholipid bilayers. Z. Naturforsch. 54c, 1089-1095.
24. Suwalsky M., Hernández P., Villena F., and Sotomayor C. P. (2000), The anticancer drug cisplatin interacts with the human erythrocyte membrane. Z. Naturforsch. 55c, 461-466.
25. Takeuchi M. (2001), Skin toxicity associated with bolus infusion of low-dose cytarabine. Jap. J. Clin. Hem. 42, 216-217.
26. Van der Berg H., van der Flier M., and van der Wetering M. (2001), Cytarabine-induced aseptic meningitis. Leukemia 15, 697-699.
27. Yeshurun M. and Marsot K. (2001), Acute cerebellar syndrome following intermediate-dose cytarabine. British J. Haem. 113, 846-846.